Statins for heart failure: Still caught in no man's land?

Clinical Science

Volumn 116, Issue 1, 2009, Pages 37-39

  von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atorvastatin; Heart failure; Inflammation; Interleukin 10; Myocardial infarction

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; HEPTANOIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRROLE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE INCREASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC HEART DISEASE; NOTE; PRIORITY JOURNAL; BLOOD; EVIDENCE BASED MEDICINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EVIDENCE-BASED MEDICINE; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; PYRROLES;

EID: 60549094068     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080530     Document Type: Note

References (30)

1. von Haehling, S and Anker, S. D. (2005) Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart 91, 1-2
2. von Haehling, S., Anker, S. D. and Bassenge, E. (2003) Statins and the role of nitric oxide in chronic heart failure. Heart Failure Rev. 8, 99-106
3. Wong, W. W., Tan, M. M., Xia, Z., Dimitroulakos, J., Minden, M. D. and Penn, L. Z. (2001) Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin. Cancer Res. 7, 2067-2075
4. Jakobisiak, M., Bruno, S., Skierski, J. S. and Darzynkiewicz, Z. (1991) Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. U.S.A. 88, 3628-3632
5. Landmesser, U., Engberding, N., Bahlmann, F. H. et al. (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110, 1933-1939
6. Tousoulis, D., Antoniades, C., Bosinakou, E. et al. (2005) Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178, 359-363
7. Pahan, K., Sheikh, F. G., Namboodiri, A. M. and Singh, I. (1997) Lovastatin and phenyl-acetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100, 2671-2679
8. Solheim, S., Seljeflot, I., Arnesen, H., Eritsland, J. and Eikvar, L. (2001) Reduced levels of TNFα in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 157, 411-415
9. Pasceri, V., Chang, J. S., Willerson, J. T. et al. (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103, 2531-2534
10. Albert, M. A., Danielson, E., Rifai, N. and Ridker, P. M. (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, J. Am. Med. Assoc. 286, 64-70
11. Anker, S. D. and von Haehling, S. (2004) Inflammatory mediators in chronic heart failure: an overview. Heart 90, 464-470
12. Rauchhaus, M., Doehner, W., Francis, D. P. et al. (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060-3067
13. Ferrari, R., Bachetti, T., Confortini, R. et al. (1995) Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92, 1479-1486
14. Mann, D. L., McMurray, J. J., Packer, M. et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602
15. Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A. and Willerson, J. T. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140
16. von Haehling, S. and Anker, S. D. (2005) Future prospects of anticytokine therapy in chronic heart failure. Expert Opin. Investig. Drugs 14, 163-176
17. Kjekshus, J., Apetrei, E., Barrios, V. et al. (2007) Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261
18. GISSI-HF Investigators (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231-1239
19. Krum, H., Ashton, E., Reid, C. et al. (2007) Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J. Card. Failure 13, 1-7
20. Ratcliffe, S. (2003) The Oxford Dictionary of Quotations by Subject, Oxford University Press, New York
21. von Haehling, S. and Anker, S. D. (2006) Statins. In Pharmacotherapy of Cachexia (Hofbauer, K. G., Anker, S. D., Inui, A. and Nicholson, J. R., eds.), pp. 425-450, Taylor & Francis, London
22. Liao, J. K. and Laufs, U. (2005) Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118
23. Horwich, T. B., Hamilton, M. A., Maclellan, W. R. and Fonarow, G. C. (2002) Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Failure 8, 216-224
24. Rauchhaus, M., Clark, A. L., Doehner, W. et al. (2003) The relationship between cholesterol and survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 1933-1940
25. Rauchhaus, M., Coats, A. J. and Anker, S. D. (2000) The endotoxin-lipoprotein hypothesis. Lancet 356, 930-933
26. von Haehling, S., Schefold, J. C., Springer, J. and Anker, S. D. (2008) The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond. Heart Failure Clin. 4, 141-151
27. Anker, S. D., Egerer, K. R., Volk, H. D., Kox, W. J., Poole-Wilson, P. A. and Coats, A. J. (1997) Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am. J. Cardiol. 79, 1426-1430
28. Stumpf, C., Petzi, S., Seybold, K. et al. (2009) Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin. Sci. 116, 45-52
29. Girndt, M. and Kohler, H. (2003) Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrol. Dial. Transplant. 18, 1976-1979
30. Anker, S. D. and Coats, A. J. (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86, 123-130